A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2014

At a glance

  • Drugs Voxtalisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Jul 2012 Planned End Date changed from 1 Jul 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Planned end date changed from 1 Feb 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 15 Nov 2011 Planned end date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top